1 completed, 1 recruiting, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
Follow Angiomyolipoma: new trials by email Literature Review of Angiomyolipoma trials Research Report on Angiomyolipoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ivonescimab in the Treatment of Multiple Advanced Tumors Ivocizumab - Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma | Phase 2 | Recruiting | Fudan University | 400 | 2024-11-20 | 2025-08-24 |
| A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa BEZ235 - Malignant PEComa (Perivascular Epithelioid Cell Tumors) | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2012-09-01 | 2013-08-02 | |
| RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS Rapamycin - Nonmalignant Neoplasm, Tuberous Sclerosis | Phase 2 | Completed | Dana-Farber Cancer Institute | 36 | 2005-12-20 | 2022-04-25 |
Perivascular Epithelioid Cell Neoplasms (2) · Tuberous Sclerosis (2) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Transitional Cell (1) · Kidney Neoplasms (1) · Neoplasms (1) · Paget Disease, Extramammary (1) · Paraganglioma (1) · Penile Neoplasms (1) · Pheochromocytoma (1) · Prostatic Neoplasms (1) · Rhabdomyosarcoma (1)
Neoplasms by Histologic Type (3) · Neoplasms, Adipose Tissue (3) · Neoplasms, Connective and Soft Tissue (3) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hamartoma (2) · Heredodegenerative Disorders, Nervous System (2) · Malformations of Cortical Development (2) · Malformations of Cortical Development, Group I (2) · Neoplasms (2) · Neoplasms, Multiple Primary (2) · Neoplastic Syndromes, Hereditary (2) · Nervous System Diseases (2) · Nervous System Malformations (2)
Sirolimus (1) · dactolisib (1)
Dana-Farber Cancer Institute (1) · Fudan University (1) · Novartis Pharmaceuticals (1)
China (1) · Spain (1) · United States (1)
Hongxia Wang, Doctor (1) · Sandra Dabora, MD, PhD (1)
P30CA006516 (1), R01CA107164 (1)